Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.39 USD 1.19% Market Closed
Market Cap: 521.6m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

Mereo Biopharma Group PLC
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mereo Biopharma Group PLC
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Mereo Biopharma Group PLC
NASDAQ:MREO
Capital Expenditures
ÂŁ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Capital Expenditures
-$169k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Capital Expenditures
-ÂŁ26.7m
CAGR 3-Years
-106%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Capital Expenditures
-$916k
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Capital Expenditures
-ÂŁ5.4m
CAGR 3-Years
-21%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Capital Expenditures
-ÂŁ24.7m
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
-14%
No Stocks Found

Mereo Biopharma Group PLC
Glance View

Market Cap
521.6m USD
Industry
Biotechnology

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

MREO Intrinsic Value
2.23 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Mereo Biopharma Group PLC's Capital Expenditures?
Capital Expenditures
0 GBP

Based on the financial report for Dec 31, 2023, Mereo Biopharma Group PLC's Capital Expenditures amounts to 0 GBP.

Back to Top